RUA Life Sciences PLC Directorate Change (4361I)
December 11 2020 - 8:46AM
UK Regulatory
TIDMRUA
RNS Number : 4361I
RUA Life Sciences PLC
11 December 2020
RUA Life Sciences plc
("RUA", the "Company" or the "Group")
Directorate Change
RUA Life Sciences plc (AIM:RUA), the holding company of a group
of medical device businesses focused on the exploitation of
Elast-Eon(TM), a long-term implantable biostable polymer ,
announces that Gordon Wright has resigned as a non-executive
Director of the Company with effect from 10 December 2020.
As previously reported in the Company's audited results for the
year ended 31 March 2020, Gordon, who was the founder of the
predecessor AorTech business, has decided to retire from the Board
now that the business has been re-established with an exciting
future ahead of it. The Directors wish to thank Gordon for his
support and guidance over the years and look forward to working
with him in his new role as Honorary Life President.
The search for a replacement non-executive Director who will
also chair the Company's audit committee is nearing completion and
a further announcement will be made in due course.
For further information contact:
RUA Life Sciences plc Tel: +44 (0)7730 718296
Bill Brown, Executive Chairman
Shore Capital Tel: +44 (0)20 7408 4090
Tom Griffiths / David Coaten
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
improving and enabling medical devices with Elast-Eon(TM) , the
world's leading long-term implantable polyurethane.
Whether it is licensing Elast-Eon(TM) , manufacturing a device
or component or developing next generation medical devices, a RUA
Life Sciences business is pursuing our vision.
Elast-Eon (TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 7
million implants and over 14 years of successful clinical use,
RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units are:
RUA Medical : End-to-end contract developer and manufacturer
of medical devices and implantable fabric specialist.
RUA Biomaterials Licensor of Elast-Eon(TM) polymers to the medical
: device industry.
RUA Vascular : Development of large bore polymer sealed grafts
and soft tissue patches.
RUA Structural Development of tri leaflet polymeric heart valves.
Heart :
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAZFLFFBLLZFBX
(END) Dow Jones Newswires
December 11, 2020 09:46 ET (14:46 GMT)
Aortech (LSE:AOR)
Historical Stock Chart
From Apr 2024 to May 2024
Aortech (LSE:AOR)
Historical Stock Chart
From May 2023 to May 2024